Multi-pronged molecular insights into flavonoid-mediated inhibition of squalene epoxidase: a pathway to novel therapeutics
RSC Advances,
Journal Year:
2025,
Volume and Issue:
15(5), P. 3829 - 3848
Published: Jan. 1, 2025
Apigenin-7-O-glucoside,
silibinin,
and
baicalin
are
potent
squalene
epoxidase
inhibitors
with
promising
therapeutic
potential.
Integrative
in
silico
experimental
studies
pave
the
way
for
hypercholesterolemia
antifungal
therapies.
Language: Английский
The Significance of Mono‐ and Dual‐Effective Agents in the Development of New Antifungal Strategies
Cengiz Zobi,
No information about this author
Öztekin Algül
No information about this author
Chemical Biology & Drug Design,
Journal Year:
2025,
Volume and Issue:
105(1)
Published: Jan. 1, 2025
ABSTRACT
Invasive
fungal
infections
(IFIs)
pose
significant
challenges
in
clinical
settings,
particularly
due
to
their
high
morbidity
and
mortality
rates.
The
rising
incidence
of
these
infections,
coupled
with
increasing
antifungal
resistance,
underscores
the
urgent
need
for
novel
therapeutic
strategies.
Current
drugs
target
cell
membrane,
wall,
or
intracellular
components,
but
resistance
mechanisms
such
as
altered
drug‐target
interactions,
enhanced
efflux,
adaptive
cellular
responses
have
diminished
efficacy.
Recent
research
has
highlighted
potential
dual
inhibitors
that
simultaneously
multiple
pathways
enzymes
involved
growth
survival.
Combining
pharmacophores,
lanosterol
14α‐demethylase
(CYP51),
heat
shock
protein
90
(HSP90),
histone
deacetylase
(HDAC),
squalene
epoxidase
(SE)
inhibitors,
led
development
compounds
activity
reduced
resistance.
This
dual‐target
approach,
along
chemical
scaffolds,
not
only
represents
a
promising
strategy
combating
is
also
being
utilized
anticancer
agents.
review
explores
new
agents
employ
mono‐,
dual‐,
multi‐target
strategies
combat
IFIs.
We
discuss
emerging
targets,
mechanisms,
innovative
approaches
offer
hope
managing
challenging
infections.
Language: Английский
Multidimensional insights into squalene epoxidase drug development: in vitro mechanisms, in silico modeling, and in vivo implications
Expert Opinion on Therapeutic Targets,
Journal Year:
2025,
Volume and Issue:
unknown
Published: April 30, 2025
Squalene
epoxidase
(SQLE)
is
a
pivotal
enzyme
in
sterol
biosynthesis,
catalyzing
the
conversion
of
squalene
to
2,3-oxidosqualene.
Beyond
its
core
role
cholesterol
homeostasis,
SQLE
implicated
cancer,
hypercholesterolemia,
and
fungal
infections,
positioning
it
as
valuable
therapeutic
target.
We
conducted
comprehensive
literature
search
across
primary
databases
gather
vitro,
silico,
vivo
evidence
on
SQLE.
This
review
explores
enzyme's
structural
functional
features,
including
substrate
specificity
catalytic
mechanisms,
examines
inhibitor
interactions.
Computational
methods
predict
-
dynamics,
guiding
drug
design,
while
investigations
clarify
SQLE's
metabolic
disorders
tumorigenesis.
Challenges
include
resistance
study
discrepancies,
but
emerging
technologies,
such
cryo-electron
microscopy
CRISPR
editing,
offer
new
avenues
for
deeper
exploration.
an
underexplored
yet
promising
target,
with
particular
relevance
oxidative
stress,
ferroptosis,
gut
microbiota
research.
Overcoming
current
barriers
through
advanced
technologies
multidisciplinary
strategies
could
propel
SQLE-targeted
treatments
into
clinical
practice,
supporting
precision
medicine
broader
translational
applications.
Language: Английский
Unveiling the Molecular Mechanisms of Squalene Epoxidase Inhibition by Flavonoids from Erythrina speciosa: Integrative Computational and Experimental Insights
Revista Brasileira de Farmacognosia,
Journal Year:
2025,
Volume and Issue:
unknown
Published: May 5, 2025
Language: Английский
Dynamics of Sqle under Electric Field Exposure
Biochemical and Biophysical Research Communications,
Journal Year:
2025,
Volume and Issue:
unknown, P. 151993 - 151993
Published: May 1, 2025
Language: Английский
Targeting squalene epoxidase in the treatment of metabolic-related diseases: current research and future directions
Mingzhu Chen,
No information about this author
Yuting Yang,
No information about this author
Shiting Chen
No information about this author
et al.
PeerJ,
Journal Year:
2024,
Volume and Issue:
12, P. e18522 - e18522
Published: Nov. 22, 2024
Metabolic-related
diseases
are
chronic
caused
by
multiple
factors,
such
as
genetics
and
the
environment.
These
difficult
to
cure
seriously
affect
human
health.
Squalene
epoxidase
(SQLE),
second
rate-limiting
enzyme
in
cholesterol
synthesis,
plays
an
important
role
synthesis
alters
gut
microbiota
tumor
immunity.
Research
has
shown
that
SQLE
is
expressed
many
tissues
organs
involved
occurrence
development
of
various
metabolic-related
diseases,
cancer,
nonalcoholic
fatty
liver
disease,
diabetes
mellitus,
obesity.
inhibitors,
terbinafine,
NB598,
natural
compounds,
their
derivatives,
can
effectively
ameliorate
fungal
infections,
cancer.
In
this
review,
we
provide
overview
recent
research
progress
on
diseases.
Further
regulation
expression
highly
for
developing
drugs
treatment
with
good
pharmacological
activity.
Language: Английский